Literature DB >> 33291702

BCG as a Vector for Novel Recombinant Vaccines against Infectious Diseases and Cancers.

Abu Salim Mustafa1.   

Abstract

Bacillus Calmette-Guérin (BCG) has been widely used globally as a prophylactic vaccine to protect against tuberculosis (TB) for about a century [...].

Entities:  

Year:  2020        PMID： 33291702      PMCID： PMC7761935          DOI： 10.3390/vaccines8040736

Source DB:  PubMed          Journal:  Vaccines (Basel)        ISSN： 2076-393X


  29 in total

1.  Can BCG vaccine protect against COVID-19 via trained immunity and tolerogenesis?

Authors:  Preetam Basak; Naresh Sachdeva; Devi Dayal
Journal:  Bioessays       Date:  2020-11-09       Impact factor: 4.345

Review 2.  The influence of vaccination against tuberculosis with the Bacillus-Calmette-Guérin(BCG) vaccine on COVID-19 incidence and mortality - review of the literature.

Authors:  Gabriela Ręka; Anna Korzeniowska; Halina Piecewicz-Szczęsna
Journal:  Przegl Epidemiol       Date:  2020

3.  Recombinant bacille Calmette-Guerin coexpressing Ag85b, CFP10, and interleukin-12 elicits effective protection against Mycobacterium tuberculosis.

Authors:  Yih-Yuan Chen; Chih-Wei Lin; Wei-Feng Huang; Jia-Ru Chang; Ih-Jen Su; Chih-Hao Hsu; Han-Yin Cheng; Shu-Ching Hsu; Horng-Yunn Dou
Journal:  J Microbiol Immunol Infect       Date:  2014-12-11       Impact factor: 4.399

4.  Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin.

Authors:  Sarah Young; Michael O'Donnell; Euan Lockhart; Bryce Buddle; Lynn Slobbe; Yi Luo; Geoff De Lisle; Glenn Buchan
Journal:  Immunol Cell Biol       Date:  2002-06       Impact factor: 5.126

5.  Priming With Recombinant BCG Expressing Novel HIV-1 Conserved Mosaic Immunogens and Boosting With Recombinant ChAdOx1 Is Safe, Stable, and Elicits HIV-1-Specific T-Cell Responses in BALB/c Mice.

Authors:  Athina Kilpeläinen; Narcís Saubi; Núria Guitart; Nathifa Moyo; Edmund G Wee; Krupa Ravi; Tomáš Hanke; Joan Joseph
Journal:  Front Immunol       Date:  2019-05-14       Impact factor: 7.561

6.  First-In-Human Trials of GamTBvac, a Recombinant Subunit Tuberculosis Vaccine Candidate: Safety and Immunogenicity Assessment.

Authors:  Daria V Vasina; Denis A Kleymenov; Victor A Manuylov; Elena P Mazunina; Egor Yu Koptev; Elena A Tukhovskaya; Arkady N Murashev; Alexander L Gintsburg; Vladimir A Gushchin; Artem P Tkachuk
Journal:  Vaccines (Basel)       Date:  2019-11-01

7.  Variable Virulence and Efficacy of BCG Vaccine Strains in Mice and Correlation With Genome Polymorphisms.

Authors:  Lu Zhang; Huan-Wei Ru; Fu-Zeng Chen; Chun-Yan Jin; Rui-Feng Sun; Xiao-Yong Fan; Ming Guo; Jun-Tao Mai; Wen-Xi Xu; Qing-Xia Lin; Jun Liu
Journal:  Mol Ther       Date:  2015-12-08       Impact factor: 11.454

Review 8.  New disease old vaccine: Is recombinant BCG vaccine an answer for COVID-19?

Authors:  Pramod Kumar Gupta
Journal:  Cell Immunol       Date:  2020-07-28       Impact factor: 4.868

9.  Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses.

Authors:  Janine Hensel; Kathleen M McAndrews; Daniel J McGrail; Dara P Dowlatshahi; Valerie S LeBleu; Raghu Kalluri
Journal:  Sci Rep       Date:  2020-10-27       Impact factor: 4.379
View more
  5 in total

Review 1.  Harnessing the Immune System with Cancer Vaccines: From Prevention to Therapeutics.

Authors:  Ilene Le; Subramanian Dhandayuthapani; Jessica Chacon; Anna M Eiring; Shrikanth S Gadad
Journal:  Vaccines (Basel)       Date:  2022-05-21

Review 2.  Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins.

Authors:  Abu Salim Mustafa
Journal:  Vaccines (Basel)       Date:  2021-01-07

3.  Complete Genome Sequence, Genome Stability and Phylogeny of the Vaccine Strain Mycobacterium bovis BCG SL222 Sofia.

Authors:  Stefan Panaiotov; Yordan Hodzhev; Vladimir Tolchkov; Borislava Tsafarova; Alexander Mihailov; Tzvetelina Stefanova
Journal:  Vaccines (Basel)       Date:  2021-03-09

4.  BCG immunotherapy inhibits cancer progression by promoting the M1 macrophage differentiation of THP‑1 cells via the Rb/E2F1 pathway in cervical carcinoma.

Authors:  Limin Liu; Wenjuan Shi; Xiao Xiao; Xuemei Wu; Haiyan Hu; Shixin Yuan; Kai Liu; Zhihua Liu
Journal:  Oncol Rep       Date:  2021-09-28       Impact factor: 3.906

Review 5.  Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.

Authors:  Fengling Feng; Ziyu Wen; Jiaoshan Chen; Yue Yuan; Congcong Wang; Caijun Sun
Journal:  Viruses       Date:  2022-03-03       Impact factor: 5.048
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.